NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On February 8, 2019, Mr. Iain Anderson provided notice that he was resigning from his position as Chief Financial Officer of Nemaura Medical, Inc. (the “Company”), effective immediately, for personal reasons. There were no disagreements between Mr. Anderson and the Company on any matter relating to the Company’s operations, policies or practices, that resulted in his resignation..
The Board of Directors and management are currently considering candidates to replace Mr. Anderson. In the interim, Mr. Dewan F.H. Chowdhury, Chief Executive Officer and President of the Company, will serve as the Chief Financial Officer.
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
